Japan's GPIF, world's largest pension fund, makes big India bet

Market pulse

From the investor's mind

Persistent Systems has secured a significant 6.5-year strategic services agreement valued at over USD 650 million, with an annual worth exceeding USD 125 million, for end-to-end cloud service operations, product development, and SRE-led operations across North America, Europe, and Asia Pacific. This single order is comparable to Persistent Systems' entire quarterly total contract value (TCV) win, and for context, their FY26 TCV was USD 2.4 billion. Aditya Kondawar highlights that Persistent Systems has also acquired an approximately 21% stake in Nagarro through an agreement with Nagarro's largest shareholder, an acquisition that expands Persistent's European presence and capabilities in enterprise resource planning and customer experience. The investor's point is that these moves demonstrate substantial growth and strategic expansion for Persistent Systems, especially considering the scale of the new order relative to their past performance and the strategic value of the Nagarro acquisition.

Word in the street

The Global Pharma Reset: China Risk Rises, India Opportunity Opens

A global pharma reset is capturing investor attention as geopolitical tensions brew between the U.S. and China. A new bill introduced in the United States, the BINSA, has sent a clear signal across the industry. The proposed legislation aims to review and potentially restrict American pharmaceutical companies from funding or sharing technology and research with Chinese biotech firms. This development could redirect a significant flow of capital and contract work, potentially opening a massive opportunity for Indian players to step in. While the bill is not yet law, the direction is clear. The debate on the street is no longer about if a shift will happen, but how quickly Indian pharma can move to capture the spoils.

Yesterday's big moves

“Heads, I win; tails, I don't lose much.”

Mohnish Pabrai